




**CME FOUNDATION OF INDIA**



**NOVEL THERAPY TO  
TREAT CKD ANEMIA IN INDIA**

**EVENT REPORT**

## About Workshop

The **CME Foundation of India** organized an academic workshop on **Novel Therapy to Treat CKD Anemia in India** on 4<sup>th</sup> February 2026 at Hotel De Sovrani, Bidhannagar, Kolkata. The session aimed to address the unmet clinical needs in the management of anemia associated with chronic kidney disease (CKD) and to explore emerging therapeutic approaches in this domain.

The workshop was attended by physicians and nephrologists from surrounding centers. The session by **Dr. Piyali Sarkar** covered multiple aspects of CKD anemia management, such as understanding the growing challenge in CKD anemia, limitations of current therapies, desidustat as a novel therapy in CKD management, its mechanism, and practical integration in clinical practice.

**Date:** 4<sup>th</sup> February 2026

**Venue:** 3<sup>rd</sup> Floor, Deciduous Hall, Hotel De Sovrani,  
Bidhannagar, Kolkata, West Bengal

**No. of participants:** 20

## Agenda

**Date:** 4<sup>th</sup> February 2026

**Time:** 7:00 p.m. to 8:00 p.m.

Topics	Speaker	Timings
Registration		7:00 p.m. – 7:10 p.m.
Welcome Note		7:10 p.m. – 7:15 p.m.
Novel Therapy to Treat CKD Anemia in India	<b>Speaker</b> Dr. Piyali Sarkar M.B.B.S., M.R.C.P. (UK), M.R.C.P. (London), F.I.S.N. <b>Chairperson</b> Dr. Jayanta Datta M.B.B.S., M.D. (Internal Medicine), D.M. (Nephrology)	7:15 p.m. – 7:55 p.m.
Vote of Thanks Followed by Dinner		7:55 p.m. – 8:00 p.m.

## Summary of the Novel Therapy to Treat CKD Anemia in India

Dr. Jayanta Datta opened the session introducing the topic on anemia associated with chronic kidney disease in India. He gave a brief highlight on the growing burden of CKD anemia and introduced Dr. Piyali Sarkar, the speaker of the session.

### The Growing Burden of Anemia in CKD

Dr. Piyali Sarkar began the session by highlighting the high prevalence of anemia among patients with chronic kidney disease (CKD) in India. She underscored its negative effects on clinical outcomes, quality of life, and overall healthcare costs. CKD-related anemia, she explained, is a multifaceted condition arising from iron deficiency, persistent inflammation, and reduced erythropoietin production. The interaction of these factors makes anemia difficult to manage and points to the need for newer therapeutic strategies beyond traditional treatments.

### Limitations in Existing Anemia Therapies

The discussion then addressed currently used treatment options, such as erythropoiesis-stimulating agents (ESAs) and iron therapy. Dr. Piyali Sarkar outlined several challenges associated with these approaches, including inconsistent efficacy, safety concerns, and limited availability in the Indian healthcare system. These issues often result in suboptimal hemoglobin control, frequent dose adjustments, and poor treatment adherence, leaving significant unmet needs in CKD-related anemia care.

### Desidustat: An Emerging Treatment Option

A major highlight of the workshop was Desidustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Dr. Piyali Sarkar explained that Desidustat enhances endogenous erythropoietin production, improves iron metabolism, and lowers hepcidin levels. By addressing multiple pathophysiological mechanisms of CKD-associated anemia, it represents a promising oral alternative to ESAs, potentially reducing the need for injections and improving patient compliance.

### Clinical Evidence for Desidustat

Dr. Piyali Sarkar reviewed clinical trial findings showing that Desidustat effectively raises and sustains hemoglobin levels across diverse patient groups, with a favorable safety and tolerability profile. She also shared real-world clinical experience supporting its effectiveness in both dialysis-dependent and non-dialysis CKD patients.

## **Application in Routine Clinical Practice**

The session concluded with practical guidance on selecting appropriate patients, determining dosing strategies, monitoring therapy, and incorporating Desidustat into everyday clinical practice. The discussion emphasized practical, patient-focused approaches aimed at optimizing treatment adherence and improving outcomes in the management of CKD-related anemia.

**At the end of the Conclave, the CME Foundation of India extended its sincere gratitude to the speaker and delegates for attending the conclave and acknowledged Zydus Lifesciences Ltd., the industry partner, for their valuable support and contribution to the success of the Conclave.**

## Snapshots of Success

### Lecture on Novel Therapy to Treat CKD Anemia in India









Developed by:

## **CME FOUNDATION OF INDIA**

Building "A" Sahney Business Centre, 27 Kirol Road, Vidyavihar (W), Mumbai - 400086  
Tel: +91 22 61798600 | Website: [www.cmefi.co.in](http://www.cmefi.co.in)